Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2024-08-01 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
关于使用暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by Shenzhen Microchip Biotechnology Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the board and supervisory committee meetings approving the use of up to 200 million RMB of idle raised funds for safe, liquid, and principal-protected investment products. The document includes background on the raised funds from IPO and convertible bonds, investment plans, risk control measures, and opinions from the supervisory board and sponsor institution. It is a regulatory announcement about the company's financing fund management and usage, not a financial report or earnings release. It does not contain financial statements or detailed financial analysis but rather a disclosure of a corporate financing activity and compliance with regulatory requirements. Therefore, it fits best under Capital/Financing Update (CAP). The document length (5861 characters) and content confirm it is a full announcement, not a brief report publication notice or certification. Confidence is high due to clear keywords like "募集资金" (raised funds), "现金管理" (cash management), board approvals, and regulatory compliance statements related to financing activities.
2024-08-01 Chinese
自愿披露关于西达本胺治疗结直肠癌获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Shenzhen Microchip Biotech Co., Ltd. regarding the approval of a clinical trial application for a drug (Chidamide) to treat colorectal cancer. It includes details about the drug, the clinical trial approval from the National Medical Products Administration, and risk warnings. The document is an announcement of a regulatory approval related to drug clinical trials and does not contain financial data, earnings, management changes, or other report types. It is not a financial report or earnings release but a regulatory announcement about clinical trial approval. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-07-23 Chinese
自愿披露关于西格列他钠联合二甲双胍治疗2型糖尿病适应症获批的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Microchip Biotech Co., Ltd. regarding the approval of a new indication for a drug (Sitagliptin combined with Metformin for type 2 diabetes). It includes details about the drug, regulatory approval from the National Medical Products Administration, and a risk warning for investors. The document is short (1275 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an announcement of a regulatory approval event related to the company's product, not a financial report or management discussion. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement about a product approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-07-19 Chinese
关于可转债转股结果暨股份变动的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the conversion results of convertible bonds and the resulting changes in share capital for Shenzhen Microchip Biotechnology Co., Ltd. It details the amount of bonds converted into shares during the quarter and cumulatively, the remaining unconverted bonds, and changes in share capital. It includes specific bond codes, conversion prices, issuance details, and regulatory approvals. The document is a formal disclosure of bond conversion and share capital changes, not a financial report, earnings release, or management discussion. It fits the category of Capital/Financing Update (CAP) as it updates on the company's financing activities and capital structure changes due to convertible bond conversions.
2024-07-01 Chinese
关于“微芯转债”2024年付息的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the interest payment on a convertible bond issued by Shenzhen Microchip Biotechnology Co., Ltd. It details the bond issuance, interest calculation, payment dates, tax information, and contact details. The document is relatively short (3452 characters) and focuses on the payment of interest for the year 2024, not on presenting financial statements or comprehensive financial data. It is an official notice about a financing instrument's interest payment rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2024-06-27 Chinese
国投证券股份有限公司关于深圳微芯生物科技股份有限公司向不特定对象发行可转换公司债券受托管理事务报告（2023年度）
Capital/Financing Update Classification · 95% confidence The document is a detailed report titled "受托管理事务报告 (2023年度)" related to the issuance and management of convertible bonds by Shenzhen Chipscreen Biosciences Co., Ltd. It includes extensive information on bond issuance approval, terms, bondholder rights, bond management, company financials for 2023, use of raised funds, and trustee duties. The content focuses on bond issuance, management, and financial performance related to the bond, not a general annual report or earnings release. It is not a brief announcement but a comprehensive report on bond trustee management and related financial data. This fits the category of Capital/Financing Update (CAP) as it deals with bond issuance and management details, fundraising, and capital structure updates.
2024-06-25 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.